News

The latest press releases, publications, and events for Innoviva Specialty Therapeutics

07.13.2024

IDSA 2024 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections

06.24.2024

Cefiderocol and Sulbactam-Durlobactam against Carbapenem-Resistant Acinetobacter baumannii

06.24.2024

Current treatment options for pneumonia caused by carbapenem-resistant Acinetobacter baumannii

06.24.2024

Sulbactam-Durlobactam, A Novel Drug for the Treatment of Multidrug-resistant Acinetobacter baumannii Infections – A Systematic Review

06.24.2024

In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals

06.24.2024

Sulbactam-durlobactam: a β-lactam/β-lactamase inhibitor combination targeting Acinetobacter baumannii

06.24.2024

Comparison of clinical outcomes for patients with monomicrobial vs polymicrobial Acinetobacter baumannii-calcoaceticus complex infections treated with sulbactam-durlobactam or colistin: A subset analysis from a phase 3 clinical trial

06.24.2024

Characterization of Acinetobacter baumannii-calcoaceticus complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK)

06.24.2024

In vitro antibacterial activity of sulbactam-durlobactam in combination with other antimicrobial agents against Acinetobacter baumannii-calcoaceticus complex

06.24.2024

In vitro antibacterial activity of sulbactam-durlobactam in combination with other antimicrobial agents against Acinetobacter baumannii-calcoaceticus complex